Myricx Bio is developing small molecule inhibitors of cMyc, a protein that is deregulated in over 70% of all human cancers. The company has strategic partnerships with Australia’s leading integrated cancer centre, the Peter MacCallum Cancer Centre, and Australia’s premier government research organisation, CSIRO.
Myricx Bio is based in Melbourne, Australia and conducts its research and discovery activities through service providers and research collaborators in Europe, UK, USA and Australia.
https://myricxbio.com/
Myricx Bio is based in Melbourne, Australia and conducts its research and discovery activities through service providers and research collaborators in Europe, UK, USA and Australia.
https://myricxbio.com/
Total raised: $115.69M
Investors 1
| Date | Name | Website |
| 07.11.2023 | Brandon Ca... | brandoncap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.07.2024 | Series A | $115.69M | - |
Mentions in press and media 13
| Date | Title | Description |
| 28.07.2025 | Brandon Capital: Fund Six Closed At Over A$439 Million | Brandon Capital, Australasia’s leading life sciences venture capital firm, has announced the final close of its sixth fund, the Brandon BioCatalyst Fund Six (BB6), totaling A$439 million. New investors in BB6 include the Western Australia G... |
| 21.10.2024 | Despite faltering VC funding in Europe, healthtech made a comeback in Q3 | European startup funding faltered in Q3 2024, with startups raising a total of $11.3 billion – down 35% compared to the same time last year according to Dealroom. However, total investment in European tech so far in 2024 totals $40.9 billio... |
| 16.10.2024 | UK Startups: A Resilient Landscape Amidst VC Funding Challenges | The UK startup scene is a vibrant tapestry, woven with ambition and innovation. Despite facing headwinds, it remains a beacon of opportunity. Recent reports reveal a significant drop in venture capital (VC) funding during the third quarter ... |
| 15.10.2024 | Even in Record Low Quarter, UK Startups Top Europe in VC Funding | Funding for UK startups dropped dramatically in the third quarter of 2024, according to recent figures, as founders feel the pressure to find new sources of investment. Venture capital funding for startups fell by 50% from the previous quar... |
| 12.07.2024 | Myricx Bio: Revolutionizing Cancer Treatment with Novel Payloads | Myricx Bio, a UK-based biotech company, has secured a whopping £90 million in Series A funding to develop a groundbreaking class of payloads for antibody-drug conjugates (ADCs). Led by Novo Holdings and Abingworth, this investment marks a s... |
| 11.07.2024 | Myricx Bio Raises £90 Million In Series A To Develop Pay Class For Antibody-Drug Conjugates | Life science investor Novo Holdings announced that it has co-led a £90 million ($114 million) Series A financing for Myricx Bio, the largest European biotech Series A funding this year. Myricx Bio is a UK biotech company focusing on the dis... |
| 08.07.2024 | Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development | London, UK, 8 July 2024 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its series A financi... |
| 08.07.2024 | Myricx Bio Raises £90M in Series A Funding | Myricx Bio, a London, UK-based biotech company focusing on the discovery and development of a novel payload class for antibody-drug conjugates (ADCs), raised £90M ($114M) in Series A funding. The round was led by Novo Holdings and Abingwort... |
| 04.06.2024 | Brandon Capital Announces Sixth Fund with A$270 million (US$180 million) Initial Close to Drive Life Science Innovation | MELBOURNE, Australia – 4 June 2024 – Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the launch of its sixth fund, Brandon Capital Fund VI, with an initial close at A$270 million (US$180 million). ... |
| 27.11.2023 | Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies | Scientists Uncover Central Role of N-Myristoylation in Senescence |
Show more